After finding itself among the most oversold sectors last year, biotech is having its best start to a year since 2012 – a rally fueled by takeover speculation and some promising drug trial data presentations at the recent J.P. Morgan Health Care Conference. CLICK HERE.
Biotech Is On The Mend
- by Ashley Hayes
Tags:Biotech InvestmentsBiotech StocksInvestingJ.P Morgan Health Care ConferenceOversold Biotech SectorStock Market